Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maze Therapeutics (MAZE) Liabilities and Shareholders Equity (2024 - 2026)

Maze Therapeutics' Liabilities and Shareholders Equity history spans 3 years, with the latest figure at $419.7 million for Q1 2026.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 26.1% to $419.7 million in Q1 2026 year-over-year; TTM through Mar 2026 was $1.5 billion, a 169.0% increase, with the full-year FY2025 number at $397.1 million, up 65.1% from a year prior.
  • Liabilities and Shareholders Equity hit $419.7 million in Q1 2026 for Maze Therapeutics, up from $397.1 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for MAZE hit a ceiling of $422.1 million in Q3 2025 and a floor of $240.5 million in Q4 2024.
  • Historically, Liabilities and Shareholders Equity has averaged $352.6 million across 3 years, with a median of $365.0 million in 2025.
  • Biggest five-year swings in Liabilities and Shareholders Equity: skyrocketed 65.1% in 2025 and later grew 26.1% in 2026.
  • Tracing MAZE's Liabilities and Shareholders Equity over 3 years: stood at $240.5 million in 2024, then skyrocketed by 65.1% to $397.1 million in 2025, then grew by 5.69% to $419.7 million in 2026.
  • Business Quant data shows Liabilities and Shareholders Equity for MAZE at $419.7 million in Q1 2026, $397.1 million in Q4 2025, and $422.1 million in Q3 2025.